Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock Series X Preferred Stock	Common stock	Additional Paid-in Capital	Deficit Accumulated	Series X Preferred Stock	Total
Balance, beginning of period at Dec. 31, 2019		$ 2	$ 259,315	$ (223,597)		$ 35,720
Balance, beginning of period (in shares) at Dec. 31, 2019		2,072,266
Increase (Decrease) in Shareholders' Equity
Issuance of stock, net of issuance costs		$ 1	24,558			24,559
Issuance of stock, net of issuance costs (in shares)		881,666
Issuance of common stock for at-the-market offerings, net of issuance costs			16,268			16,268
Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)		392,288
Proceeds from exercises of options		$ 1	31			32
Proceeds from exercises of options (in shares)		1,166
Stock-based compensation expense			1,390			1,390
Net loss				(37,300)		(37,300)
Balance, end of period at Dec. 31, 2020		$ 4	301,562	(260,897)		$ 40,669
Balance, end of period (in shares) at Dec. 31, 2020		3,347,386				3,347,386
Increase (Decrease) in Shareholders' Equity
Issuance of stock, net of issuance costs	$ 84,696		19,565			$ 104,261
Issuance of stock, net of issuance costs (in shares)	35,573
Issuance of preferred stock and common stock upon acquisition of Quellis	$ 156,185		8,098			164,283
Issuance of common stock upon acquisition of Quellis (in shares)	50,504	555,444
Issuance of common stock upon the conversion of preferred stock	$ (168,920)	$ 9	168,911
Issuance of common stock upon the conversion of preferred stock (in shares)	(54,622)	9,103,664			9,103,664
Fair value adjustment to acquired Quellis warrants			1,157			1,157
Accretion of preferred stock discount	$ 24,437		(24,437)
Proceeds from exercises of options			23			$ 23
Proceeds from exercises of options (in shares)		10,470				10,470
Reclassification of equity classified warrants			3,468			$ 3,468
Fractional shares eliminated pursuant to reverse stock split		(9)
Stock-based compensation expense			3,362			3,362
Net loss				(194,912)		(194,912)
Balance, end of period at Dec. 31, 2021	$ 96,398	$ 13	$ 481,709	$ (455,809)		$ 122,311
Balance, end of period (in shares) at Dec. 31, 2021	31,455	13,016,955				13,016,955